Crenezumab

Drug Profile

Crenezumab

Alternative Names: Anti-amyloid-beta monoclonal antibody; Anti-Aβ mAb; MABT5102A; R 5490245; RG 7412

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator AC Immune; Universidad de Antioquia
  • Developer AC Immune; Chugai Pharmaceutical; Genentech; Universidad de Antioquia
  • Class Antibodies; Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 28 Feb 2017 Genentech plans a phase III CREAD2 trial for Alzheimer's disease
  • 15 Dec 2016 Adverse events and pharmacokinetics data from a phase I trial in Alzheimer's disease released by AC Immune
  • 01 Mar 2016 Phase-I clinical trials in Alzheimer's disease in Japan (IV) (JapicCTI-163210)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top